| Drug ID: | Drug41 |
|---|---|
| Drug Name: | Prednisolone |
| CID: | 5755 |
| DrugBank ID: | DB00860 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05341401, , NCT00299013, , NCT00984568 |
| Molecular Formula: | C21H28O5 |
| Molecular Weight: | 360.4 g/mol |
| Isomeric SMILES: | C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O |
| Synonyms: | prednisolone; 50-24-8; Metacortandralone; Hydroretrocortine; Delta-Cortef; Deltacortril; Deltahydrocortisone; Codelcortone; Cortalone; Prenolone |
| Phase 0: | 2 |
| Phase 1: | 68 |
| Phase 2: | 199 |
| Phase 3: | 211 |
| Phase 4: | 146 |
| Description: | A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem] |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt373 | 5755 | Prednisolone | 2539 | G6PD | Homo sapiens (human) | None | |
| dt374 | 5755 | Prednisolone | 5243 | ABCB1 | Homo sapiens (human) | 18310528 | ABCB1 results in decreased susceptibility to prednisolone |
| dt375 | 5755 | Prednisolone | 43 | ACHE | Oreochromis mossambicus (Mozambique tilapia) | 2743920 | Prednisolone inhibits the reaction [benthiocarb results in decreased activity of ACHE protein] |
| dt376 | 5755 | Prednisolone | 57007 | ACKR3 | Homo sapiens (human) | 19192274 | Prednisolone results in decreased expression of ACKR3 mRNA |
| dt377 | 5755 | Prednisolone | 2180 | ACSL1 | Homo sapiens (human) | 17379860 | Prednisolone results in increased expression of ACSL1 mRNA |
| dt378 | 5755 | Prednisolone | 135 | ADORA2A | Homo sapiens (human) | 19192274 | Prednisolone results in decreased expression of ADORA2A mRNA |
| dt379 | 5755 | Prednisolone | 196 | AHR | Mus musculus (house mouse) | 30203046 | Prednisolone results in increased activity of AHR protein |
| dt380 | 5755 | Prednisolone | 11997 | Akr1b7 | Rattus norvegicus (Norway rat) | 21149847 | Prednisolone inhibits the reaction [freund's adjuvant results in increased expression of AKR1B7 mrna] |
| dt381 | 5755 | Prednisolone | 213 | ALB | Homo sapiens (human) | 3404815 | Prednisolone results in increased expression of ALB protein |
| dt382 | 5755 | Prednisolone | 213 | ALB | Rattus norvegicus (Norway rat) | 30276927 | Montelukast inhibits the reaction [prednisolone results in decreased secretion of ALB protein]|prednisolone results in decreased secretion of ALB protein |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00299013 | Study of COLAL-PRED in the Treatment of Moderate Acute Ulcerative Colitis | PHASE3 | COMPLETED | Alizyme | Ulcerative Colitis | DRUG: COLAL-PRED|DRUG: Prednisolone | Details |
| NCT00984568 | Conventional Step-Up Versus Infliximab Monotherapy in Patients With Ulcerative Colitis (P05553) | PHASE3 | TERMINATED | Merck Sharp & Dohme LLC | Colitis, Ulcerative | BIOLOGICAL: Infliximab|DRUG: Prednisolone|DRUG: 5… | Details |
| NCT01941589 | Corticosteroids+5-aminosalicylic Acid Compared to Corticosteroids in the Treatment of Moderate-severe Ulcerative Colitis | PHASE4 | COMPLETED | Sheba Medical Center | Ulcerative Colitis | DRUG: oral 5-ASA+/-topical 5-ASA+IV corticosteroi… | Details |
| NCT03219359 | Autologous Stem Cell Transplant for Crohn's Disease | PHASE2 | RECRUITING | Aaron Etra | Crohn Disease | PROCEDURE: Autologous stem cell transplant|DRUG: … | Details |
| NCT00152620 | Dexamethasone Versus Methylprednisolone for the Treatment of Active Inflammatory Bowel Disease | None | TERMINATED | University of Chicago | Inflammatory Bowel Disease (IBD) | DRUG: Dexamethasone|DRUG: Methylprednisolone | Details |
| CTIS2023-508913-18-00 | Transfer of prednisolone into human breast milk and plasma of breastfeeding children - A low intervention cohort study with biobanking of breast milk and plasma | PHASE4 | Recruiting | Uppsala Universitet | Reumatoid Arthritis, SLE, myositis, psoriatric ar… | Product Name: , Product Code:SCP1158234, Pharmace… | Details |
| ACTRN12622001434785 | Maintaining Remission of Ulcerative Colitis with __Faecal Microbiota Transplantation: the MR-UC-FMT Trial | Not Available | Not Recruiting | Central Adelaide Local Health Network | Ulcerative Colitis;Inflammatory Bowel Disease; U… | All patients will receive Prednisolone 50mg oral … | Details |
| NL-OMON25521 | Microbiota targeted therapy as alternative for prednisolone and biologicals in IBD patients during the current COVID-19 threat: a prospective study addressing the safety of Budesonide in combination with rifaximin or the Crohns Disease Exclusion Diet (CDED) | Not Available | No | Nestlé 23/08/2021 | None | The results of this prospective study may result … | Details |
| JPRN-UMIN000030000 | The efficacy and safety of topical budezonide for pouchitis after restorative proctocolectomy in patients with ulcerative colitis. - The efficacy and safety of topical budezonide for pouchitis. | PHASE1 | Not Recruiting | Department of Inflammatory Bowel Disease Hyogo College of Medicine | ulcerative colitis pouchitis | Topical budesonido 2weeks of 2mg daily Topical … | Details |
| CTRI/2017/10/010160 | Evaluation of a Peri-Operative Low Dose Steroid Regimen for Steroid Treated Inflammatory Bowel Disease patients A Prospective Randomised Study | PHASE2|PHASE3 | Recruiting | AIIMS | Health Condition 1: null- patient having infalmma… | Intervention1: Low dose Steroid (LDS) Regimen: Pa… | Details |
| ISRCTN23541842 | The auxiliary diagnostic value of fissured tongue on axial and peripheral joint dysfunction in Ankylosing Spondylitis | Not Available | Not Recruiting | Zhejiang University Of Chinese Medicine | Ankylosing spondylitis Musculoskeletal Diseases … | Participants are screened and undergo a clinical … | Details |
| EUCTR2010-020448-37-NL | Randomized placebo-controlled multicenter exploratory Phase IIA study to assess the safety and efficacy of PEG-liposomal prednisolone sodium phosphate (Nanocort) in subjects with active ulcerative colitis. | Not Available | Not Recruiting | Enceladus Pharmaceuticals | Active Ulcerative Colitis MedDRA version: 14.1_L… | Product Name: PEG-liposomal prednisolone sodium p… | Details |
| ISRCTN81965907 | The value of faecal calprotectin (CPT) in monitoring the response to treatment of patients with inflammatory bowel disease | Not Available | Not Recruiting | Department of Health (UK) | Inflammatory bowel disease Digestive System Cro… | Patients with active inflammatory bowel disease w… | Details |
| NCT05587673 | High Dose Steroid Therapy to Treat Flares in Patients With Inflammatory Bowel Disease (IBD) | PHASE1 | COMPLETED | Stanford University | Inflammatory Bowel Diseases|Crohn Disease|Ulcerat… | DRUG: Methylprednisolone | Details |
| NCT00955123 | Effects of Prednisolone and Infliximab on the Regulation of Urea Synthesis in Active Inflammatory Bowel Disease | None | COMPLETED | University of Aarhus | Inflammatory Bowel Diseases | None | Details |
| NCT05341401 | Budesonide Multimatrix(MMX) Versus Prednisolone in Management of Mild to Moderate Ulcerative Colitis | PHASE2|PHASE3 | UNKNOWN | Assiut University | Ulcerative Colitis Chronic | DRUG: Budesonide MMX|DRUG: Prednisolone | Details |
| NCT05867329 | A Trial for Acute Severe Ulcerative Colitis | PHASE4 | RECRUITING | Berinstein, Jeffrey | Ulcerative Colitis Acute | DRUG: Cyclosporine Injection (IV)|DRUG: Cyclospor… | Details |
| NCT02921555 | Endovenous Corticosteroid Pulses in Moderate Ulcerative Colitis | PHASE4 | TERMINATED | Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa | Ulcerative Colitis | DRUG: Methylprednisolone|DRUG: Prednisone | Details |
| EUCTR2008-005903-25-DE | Exploratory, open-label study to demonstrate efficacy, safety and tolerability of SC12267 (35 mg) in patients with inflammatory bowel disease (Crohn's disease and ulcerative colitis) | Not Available | Not Recruiting | 4SC AG | inflammatory bowel disease (Crohn's disease and u… | Product Name: SC12267 Product Code: SC12267 Pharm… | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Prednisolone pharmacokinetics in dogs with protein-losing enteropathy
PMID: 39715442
Year: 2025
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: It is unknown if glucocorticoid malabsorption contributes to the approximate 50% treatment failure rate in dogs with protein-losing enter…
Effects of prednisolone tapering on effectiveness of infliximab in patients wit…
PMID: 38719549
Year: 2024
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND OBJECTIVE: The influence of concomitant prednisolone on clinical outcomes and safety in infliximab-treated ulcerative colitis (UC) pat…
3D-printed prednisolone phosphate suppositories with tunable dose and rapid rel…
PMID: 38042381
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Established medicines are often not tailored to the needs of the pediatric population, causing difficulties with administration or dosing. Three-dime…
Possible genetical predictors of efficacy and safety of budesonide-MMX in patie…
PMID: 36811412
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Budesonide-MMX is a topically active corticosteroid degraded by cytochrome-P450 enzymes, resulting in favorable side-effect profile. We a…
Perioperative Low-Dose Prednisolone Treatment Has Beneficial Effects on Postope…
PMID: 36638152
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND AND AIMS: High-dose glucocorticoid treatment has been identified as a risk factor for anastomotic leakage in patients with inflammatory bo…
Resolution of Laryngeal Ulceration with Prednisolone Therapy in a Patient with …
PMID: 36450464
Year: 2023
Relationship Type:
Treatment
Score: 6.5
A 23-year-old man diagnosed with Crohn's disease (CD) was treated with infliximab. He developed new-onset sore throat and dysphagia during admission,…
Comparing adipose-derived mesenchymal stem cells with prednisolone for the trea…
PMID: 35713592
Year: 2022
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: The objective of this study was to compare the efficacy of feline mesenchymal stem cells (fMSC) with prednisolone as a treatment for infl…
Evaluation of the endoscopic treatment with topical prednisolone administration…
PMID: 35195075
Year: 2021
Relationship Type:
Treatment
Score: 6.5
<br><b>Introduction:</b> The prevalence of Crohn's disease amounts to 5.9 cases per 100,000 population. Complications such as intes…
The Effectiveness of Methylprednisolone as a Premedication Among the Pediatric …
PMID: 34690297
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Administering medications prior to infliximab infusions to prevent infusion-related infliximab reactions is a common practice in the United States. H…
Prednisolone versus placebo addition in the treatment of patients with recent-o…
PMID: 32513294
Year: 2020
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: The symptom severity of a substantial group of schizophrenia patients (30-40%) does not improve through pharmacotherapy with antipsychoti…
The Association of methylprednisolone dosing to cessation of myotonia in a pati…
PMID: 32312586
Year: 2020
Relationship Type:
Treatment
Score: 6.5
We report the case of a patient suffering from duplicity of myotonic dystrophy type 1 and ulcerative colitis whose treatment for ulcerative colitis i…
Nanogels of a Succinylated Glycol Chitosan-Succinyl Prednisolone Conjugate: Rel…
PMID: 32235554
Year: 2020
Relationship Type:
Treatment
Score: 6.5
Recently, the potential of nanoparticles (NPs) in ulcerative colitis (UC) therapy has been increasingly demonstrated. Namely, anionic NPs have been f…
Preparation of Chondroitin Sulfate-Glycyl-Prednisolone Conjugate Nanogel and It…
PMID: 31257292
Year: 2019
Relationship Type:
Treatment
Score: 6.5
A conjugate between chondroitin sulfate (CS) and glycyl-prednisolone (GP), named CS-GP, was produced by carbodiimide coupling at a high GP/CS ratio. …
Eudragit S100 coated microsponges for Colon targeting of prednisolone
PMID: 29260916
Year: 2018
Relationship Type:
Adverse Effect
Score: 6.3
CONTEXT: Microsponge is a novel approach for targeting the drug to the colon for the management of colon ailments such as inflammatory bowel disease.…
Surface-deacetylated chitin nanofibers reinforced with a sulfobutyl ether β-cyc…
PMID: 28821031
Year: 2017
Relationship Type:
Treatment
Score: 6.3
Surface-deacetylated chitin nanofibers (SDACNFs) reinforced with a sulfobutyl ether beta-cyclodextrin (SBE-beta-CD) (NFs-CDs) gel were developed to o…
Treatment of children and adolescents with ulcerative colitis by adsorptive dep…
PMID: 23961883
Year: 2013
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Currently available drugs for the treatment of ulcerative colitis (UC) include salicylates, thiopurines, corticosteroids and new anti-tum…
Glycyrrhizin enhances therapeutic activity of a colon-specific methylprednisolo…
PMID: 23192646
Year: 2013
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: Co-administration of a reduction inhibitor and a colon-specific prodrug of a glucocorticoid susceptible to colonic reductive metabolism i…
Infliximab- and immunosuppressant-resistant Crohn's disease successfully treate…
PMID: 22761605
Year: 2012
Relationship Type:
Treatment
Score: 6.1
Activated granulocytes, monocytes, and platelets appear to be closely involved in active Crohn's disease (CD). Adsorptive granulocyte apheresis (GCAP…
Prednisolone treatment affects the performance of the QuantiFERON gold in-tube …
PMID: 21319275
Year: 2011
Relationship Type:
Treatment
Score: 6.1
BACKGROUND: During screening for latent tuberculosis infection (LTBI), before anti-tumor-necrosis-factor-alpha treatment, most patients are already r…